Corbus Pharma Reports CRB-701 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
- Clinical Trial Results: Corbus Pharma's Phase 1/2 trial for its lead asset CRB-701 showed a confirmed objective response rate of 42.9% at a 3.6 mg/kg dose for oropharyngeal squamous cell carcinoma, although the stock fell approximately 10% in premarket trading following the announcement.
- Safety Assessment: Among 317 safety-evaluable patients, CRB-701 demonstrated good safety and tolerability, with a treatment discontinuation rate of 2.8%, an improvement from 6.0% reported in October, indicating the drug's feasibility and patient acceptance in clinical use.
- Future Plans: Corbus Pharma reiterated its intention to initiate a registrational trial in summer 2026 to further validate CRB-701 as a second-line treatment option for OPSCC, reflecting the company's confidence in the long-term development of this asset.
- Data Comparison: The ESMO25 data from 2025 indicated confirmed objective response rates of 47.6% and 37.5% for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, respectively, providing crucial insights for future clinical applications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRBP
Wall Street analysts forecast CRBP stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.910
Low
38.00
Averages
46.71
High
53.00
Current: 7.910
Low
38.00
Averages
46.71
High
53.00
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corbus Pharma Reports CRB-701 Clinical Data
- Clinical Trial Results: Corbus Pharma's Phase 1/2 trial for its lead asset CRB-701 showed a confirmed objective response rate of 42.9% at a 3.6 mg/kg dose for oropharyngeal squamous cell carcinoma, although the stock fell approximately 10% in premarket trading following the announcement.
- Safety Assessment: Among 317 safety-evaluable patients, CRB-701 demonstrated good safety and tolerability, with a treatment discontinuation rate of 2.8%, an improvement from 6.0% reported in October, indicating the drug's feasibility and patient acceptance in clinical use.
- Future Plans: Corbus Pharma reiterated its intention to initiate a registrational trial in summer 2026 to further validate CRB-701 as a second-line treatment option for OPSCC, reflecting the company's confidence in the long-term development of this asset.
- Data Comparison: The ESMO25 data from 2025 indicated confirmed objective response rates of 47.6% and 37.5% for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, respectively, providing crucial insights for future clinical applications.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Corbus Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Surprise: Corbus Pharmaceuticals reported a Q1 GAAP EPS of -$1.23, beating expectations by $0.02, indicating improvements in cost control and operational efficiency despite ongoing losses.
- Strong Cash Position: As of March 31, 2026, the company had $138.2 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028, demonstrating a solid financial buffer for future activities.
- Stable Operational Plans: Based on current operational plans and expenditures, Corbus is positioned to maintain operations for the next two years, reflecting the company's confidence in its future growth despite market challenges.
- Historical Financial Data: Corbus's GAAP EPS of -$1.25 exceeded market expectations by $0.40, showcasing gradual improvements in financial performance that may attract increased investor interest.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Corbus Aligns with FDA on CRB-701 Registration Pathway
- FDA Registration Alignment: Corbus Pharmaceuticals has broadly aligned with the FDA on the registration pathway for CRB-701, enabling the company to advance the proposed study design for head and neck squamous cell carcinoma and cervical cancer, potentially accelerating the drug's approval process.
- Study Design Details: The registrational study for CRB-701 will include a randomized controlled trial comparing its efficacy and safety against physician's choice chemotherapy, with objective response rate (ORR) as the primary endpoint, and potential full approval based on overall survival (OS) benefits.
- Study Initiation Timeline: The registrational study for second-line HNSCC is expected to begin in mid-2026, while a phase 1/2 study of CRB-701 in both HNSCC and cervical cancer is ongoing, with updated data to be presented at the 2026 American Society of Clinical Oncology Annual Meeting.
- Executive Change: The company's Chief Medical Officer, Dominic Smethurst, will step down on June 30, 2026, which may impact the company's strategic direction and clinical research timelines.
See More
FDA Approves Corbus' Registrational Study Design
- Positive FDA Feedback: Corbus has achieved broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, which is expected to facilitate accelerated approval and address unmet medical needs, enhancing the company's competitive position in the market.
- Clinical Data Update: Updated monotherapy data for CRB-701 will be presented at the 2026 ASCO Annual Meeting, including clinical response durability and patient subgroup analysis, further validating its efficacy and boosting investor confidence.
- Executive Transition: Chief Medical Officer Dominic Smethurst will step down on June 30, 2026, and the company will welcome new senior leaders to better support the late-stage development of CRB-701, ensuring success during this critical phase.
- Future Outlook: Corbus plans to initiate the registrational study for CRB-701 in mid-2026 and anticipates reporting data on its combination with Keytruda in Q4 2026, further advancing the potential for registration-enabling trials.
See More
Corbus Pharma Reports CRB-701 Clinical Data
- Clinical Trial Results: Corbus Pharma's Phase 1/2 trial for its lead asset CRB-701 showed a confirmed objective response rate of 42.9% at a 3.6 mg/kg dose for oropharyngeal squamous cell carcinoma, although the stock fell approximately 10% in premarket trading following the announcement.
- Safety Assessment: Among 317 safety-evaluable patients, CRB-701 demonstrated good safety and tolerability, with a treatment discontinuation rate of 2.8%, an improvement from 6.0% reported in October, indicating the drug's feasibility and patient acceptance in clinical use.
- Future Plans: Corbus Pharma reiterated its intention to initiate a registrational trial in summer 2026 to further validate CRB-701 as a second-line treatment option for OPSCC, reflecting the company's confidence in the long-term development of this asset.
- Data Comparison: The ESMO25 data from 2025 indicated confirmed objective response rates of 47.6% and 37.5% for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, respectively, providing crucial insights for future clinical applications.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Corbus Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Surprise: Corbus Pharmaceuticals reported a Q1 GAAP EPS of -$1.23, beating expectations by $0.02, indicating improvements in cost control and operational efficiency despite ongoing losses.
- Strong Cash Position: As of March 31, 2026, the company had $138.2 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028, demonstrating a solid financial buffer for future activities.
- Stable Operational Plans: Based on current operational plans and expenditures, Corbus is positioned to maintain operations for the next two years, reflecting the company's confidence in its future growth despite market challenges.
- Historical Financial Data: Corbus's GAAP EPS of -$1.25 exceeded market expectations by $0.40, showcasing gradual improvements in financial performance that may attract increased investor interest.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Corbus Aligns with FDA on CRB-701 Registration Pathway
- FDA Registration Alignment: Corbus Pharmaceuticals has broadly aligned with the FDA on the registration pathway for CRB-701, enabling the company to advance the proposed study design for head and neck squamous cell carcinoma and cervical cancer, potentially accelerating the drug's approval process.
- Study Design Details: The registrational study for CRB-701 will include a randomized controlled trial comparing its efficacy and safety against physician's choice chemotherapy, with objective response rate (ORR) as the primary endpoint, and potential full approval based on overall survival (OS) benefits.
- Study Initiation Timeline: The registrational study for second-line HNSCC is expected to begin in mid-2026, while a phase 1/2 study of CRB-701 in both HNSCC and cervical cancer is ongoing, with updated data to be presented at the 2026 American Society of Clinical Oncology Annual Meeting.
- Executive Change: The company's Chief Medical Officer, Dominic Smethurst, will step down on June 30, 2026, which may impact the company's strategic direction and clinical research timelines.
See More
FDA Approves Corbus' Registrational Study Design
- Positive FDA Feedback: Corbus has achieved broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, which is expected to facilitate accelerated approval and address unmet medical needs, enhancing the company's competitive position in the market.
- Clinical Data Update: Updated monotherapy data for CRB-701 will be presented at the 2026 ASCO Annual Meeting, including clinical response durability and patient subgroup analysis, further validating its efficacy and boosting investor confidence.
- Executive Transition: Chief Medical Officer Dominic Smethurst will step down on June 30, 2026, and the company will welcome new senior leaders to better support the late-stage development of CRB-701, ensuring success during this critical phase.
- Future Outlook: Corbus plans to initiate the registrational study for CRB-701 in mid-2026 and anticipates reporting data on its combination with Keytruda in Q4 2026, further advancing the potential for registration-enabling trials.
See More
